NCT04870112 - A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

August 30, 2023

Study Completion Date

August 30, 2023

Conditions

Non-Small Cell Lung CancerSmall Cell Lung Cancer

Interventions

DRUG

Durvalumab

Anti-PD-L1 antibody

DRUG

Cisplatin

Chemotherapy

DRUG

Carboplatin

Chemotherapy

DRUG

Etoposide

Chemotherapy

Trial Locations (8)

Research Site, Taipei

Research Site, Christchurch

Research Site, Taipei

Research Site, Fairfax

Research Site, Majadahonda

Research Site, Taichung

Research Site, Houston

Research Site, Badalona